Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2022 08:00 ET | Source: Ultragenyx Pharmaceutical Inc.; GeneTx Biotherapeutics LLC

GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome

SARASOTA, Fla. and NOVATO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102,...
December 01, 2021 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

GeneTx and Ultragenyx Announce Presentations at Upcoming 2021 FAST Global Summit & Gala

SARASOTA, Fla. and NOVATO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102,...
February 19, 2021 09:00 ET | Source: FAST (Foundation for Angelman Syndrome Therapeutics)

FAST and SFARI to launch International Angelman Syndrome Research Council (INSYNC-AS)

DOWNERS GROVE, Ill., Feb. 19, 2021 (GLOBE NEWSWIRE) -- FAST (Foundation for Angelman Syndrome Therapeutics) and the Simons Foundation Autism Research Initiative (SFARI) today announced a...
March 18, 2020 09:27 ET | Source: Asklepios BioPharmaceutical, Inc.

AskBio Enters Research Collaboration and Licensing Agreement with University of North Carolina (UNC) for Angelman Syndrome

RESEARCH TRIANGLE PARK, N.C. and CHAPEL HILL, N.C., March 18, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading clinical-stage adeno-associated virus (AAV) gene therapy...
June 25, 2019 09:35 ET | Source: Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology’s PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental Disorder

EAST SETAUKET, NY, June 25, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that a group of neuroscientists in China and Japan reported that Lixte’s lead clinical...
March 27, 2018 13:26 ET | Source: GeneTx Biotherapeutics LLC.

GeneTx Biotherapeutics receives FDA orphan-drug designation for Angelman syndrome treatment

DOWNERS GROVE, Ill., March 27, 2018 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration has granted orphan-drug designation to GeneTx Biotherapeutics LLC’s GTX-101 for the treatment of...